Company profile: Saladax Biomedical
1.1 - Company Overview
Company description
- Provider of therapeutic drug monitoring assays and services for psychiatry and oncology, including MyCare Psychiatry for rapid blood level measurement of antipsychotic drugs and MyCare Oncology for rapid therapeutic drug level testing to assist treatment plans; also offers application sheets for measuring clozapine, olanzapine, quetiapine, and total risperidone using Beckman Coulter systems.
Products and services
- MyCare Oncology: An oncology-focused, rapid-turnaround assay service delivering therapeutic drug level testing to assist patient treatment plans
- MyCare Psychiatry: A psychiatry-specific therapeutic drug monitoring assay enabling rapid blood level measurement of antipsychotic drugs for use in psychiatry
- Total Risperidone Application Sheets: Instrument-specific manuals designed for Beckman Coulter systems, detailing procedures for determining total risperidone blood levels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Saladax Biomedical
Microarrays
HQ: United States
Website
- Description: Provider of microarray platforms and services for analyte testing, diagnostics, and personalized medicine, including pathway-focused gene expression arrays (MI PathArray), whole-genome microarrays (MI ReadyArray), DNA and protein/antibody arrays, assay development, and lab services for RNA profiling and microarray assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microarrays company profile →
LGC
HQ: United Kingdom
Website
- Description: Provider of life sciences measurement and testing solutions, delivering reference materials, genomics and agbio solutions, clinical and molecular diagnostics, analytical testing, and food and water safety testing, plus government partnership services for evidence-based decision-making, supported by expertise in regulation, accreditation, and standard setting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LGC company profile →
Dicerna
HQ: United States
Website
- Description: Provider of biotechnology research focused on discovering and developing RNA interference (RNAi)-based treatments for rare inherited liver diseases, cancers, and other liver-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dicerna company profile →
Camp4 Therapeutics
HQ: United States
Website
- Description: Provider of RNA-based therapeutics and platform technologies to restore healthy gene expression, including the RAP Platform to map regRNAs and select optimal chemistry, RNA Amplifiers to increase protein expression, programmable antisense oligonucleotide therapeutics targeting regRNA, and CMP-CPS-001 to amplify CPS1 mRNA for potential treatment of urea cycle disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Camp4 Therapeutics company profile →
Tango Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tango Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Saladax Biomedical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Saladax Biomedical
2.2 - Growth funds investing in similar companies to Saladax Biomedical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Saladax Biomedical
4.2 - Public trading comparable groups for Saladax Biomedical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →